Federally-Listed PSOs

Below is a list of PSOs that are currently listed by AHRQ. A health care provider can only obtain the confidentiality and privilege protections of the Patient Safety Act by working with a Federally-listed PSO.

Use the categories on the left to filter the list of PSOs or search a PSO name.

Note: AHRQ updates the PSO information contained within the directories weekly, as needed; changes are made when there are newly listed PSOs and/or when existing information requires revision. Changes that would otherwise be effective on a weekend day or holiday will be effective on the next business day. Information contained in the directories is based on attestations that the PSOs provide. To update PSO contact information, please use the Change of Listing Information form; to update profile information, please go to the PSO PPC Web site.

There are 93 total PSOs listed by AHRQ.

PLEASE NOTE: To search for a PSO by State, use the 2 letter state abbreviation. Example: Kansas = KS

American Data Network PSO - P0051
Component of Parent Org(s):
  • American Data Network
Effective Date and Time of Initial Listing: February 25, 2009 12:01 AM ET
PSO Mailing Address: 10809 Executive Center Drive, Searcy Building, Suite 300, Little Rock, AR 72211
PSO Phone Number: (501) 225-5533, ext. 103
Point of Contact: Stephanie Iorio
Point of Contact Phone: (501) 537-7942
Point of Contact Email: siorio@americandatanetwork.com (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 02/25/2019 through 02/24/2021
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No
Ascension Healthcare Patient Safety Organization - P0111
Component of Parent Org(s):
  • Ascension Health
    • Parent Organization Alternate Legal Name: Ascension
Effective Date and Time of Initial Listing: May 11, 2011 12:01 AM ET
PSO Mailing Address: 4600 Edmundson Road, St. Louis, MO 63134
PSO Phone Number: (314) 733-8164
Point of Contact: Jeanene Walsh
Point of Contact Phone: 620-235-7520
Point of Contact Email: jeanene.walsh@ascension.org (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 05/11/2021 through 05/10/2023
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: Yes
Louisiana Alliance for Patient Safety PSO - P0186
Component of Parent Org(s):
  • Louisiana Hospital Association
Effective Date and Time of Initial Listing: November 8, 2016 12:01 AM ET
PSO Mailing Address: 9521 Brookline Ave, Baton Rouge, LA 70809
PSO Phone Number: 225-928-0026
Point of Contact: Angela Lockhart
Point of Contact Phone: 225-928-0026, ext. 223
Point of Contact Email: alockhart@lhaonline.org (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 11/08/2020 through 11/07/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No
Texas Hospital Association (THA) Patient Safety Organization - P0135
Component of Parent Org(s):
  • Texas Hospital Association Foundation
Effective Date and Time of Initial Listing: November 14, 2012 12:01 AM ET
PSO Mailing Address: 1108 Lavaca Street, Suite 700, Austin, TX 78701
PSO Phone Number: 512-465-1000
Point of Contact: Karen Kendrick RN
Point of Contact Phone: 512-465-1091
Point of Contact Email: kkendrick@tha.org (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 11/14/2020 through 11/13/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No
The Quality Center Patient Safety Organization - P0025
Component of Parent Org(s):
  • NCHA, Inc. DBA North Carolina Healthcare Association
  • North Carolina Hospital Foundation, Inc.
Effective Date and Time of Initial Listing: December 10, 2008 12:01 AM ET
PSO Mailing Address: 2400 Weston Parkway, Cary, NC 27513
PSO Phone Number: (919) 677-4212
Point of Contact: Shelby Lassiter
Point of Contact Phone: 919-677-4134
Point of Contact Email: slassiter@ncha.org (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 12/10/2020 through 12/09/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No